(CercleFinance.com) – Sanofi ricochets below 104.38E, falls below 99E following the announcement of the absence of authorization for the sale of Cialis over the counter (the approval by the FDA seemed imminent, however, it is now asking an additional test, despite years of experimentation) but still maintains a lead of +16.5% since January 1.
Sanofi preserves for the moment the medium-term oblique support which gravitates towards 99.5E, the next one is around 95.8E, it is the ex-floor multi-tested from April 25th to May 12th.
Copyright © 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
